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Although immune reactions to collagen have been de­
scribed in several diseases, the pathophysiologic conse­
quences of collagen autoimmunity remain obscure. We 
have recently described an animal model of polyarthritis 
which can be induced in susceptible rats or mice by 
immunization with native type II collagen. Arthritis de­
velops in animals which have high levels of both cellular 
and humoral immunity to collagen. In rats, arthritis can 
be passively transferred with purified IgG antinative 
type II collagen antibodies. There is circumstantial evi­
dence that antibodies are also important for the initia­
tion of arthritis in susceptible mice. Circulating immune 
complexes do not appear to be involved and we believe 
the arthritis is caused by binding of antibodies to autol­
ogous collagen. 
There are a number of similarities between collagen­
induced arthritis and human rheumatoid arthritis (RA). 
Many histopathologic changes are similar including sy­
novitis which progresses to pannus formation, develop­
ment of marginal erosions and eventual cartilage de­
struction. Both diseases are associated with collagen 
autoimmunity which appears to be genetically linked to 
the major histocompatibility locus. However, there are 
also significant differences. In particular, the antibody 
reactivity usually found in RA is primarily directed 
against covalent structural determinants on collagen 
and not against the conformation-dependent determi­
nants on type II collagen critical to the development of 
collagen-induced arthritis. 
Immunity to collagen has also been described in other 
animal models of disease and in other human diseases 
but its relevance to their pathophysiology is unknown. 
By further characterizing the specific reactions involved 
including the nature of the immune response, its speci­
ficity and the genetic factors important in the host; 
insight may be gained into the role of collagen autoim­
munity in human disease. While significant progress has 
been made in all of these areas during the last several 
years, much remains to be learned before the relevance 
of collagen autoimmunity to any human disease is estab­
lished. 
COLLAGEN AUTOIMMUNITY IN EXPERIMENTAL 
MODELS OF DISEASE 
We have previously described an animal model of arthritis 
induced by immunization of susceptible rats with native type II 
collagen [1]. Native type II collagen was dissolved in 0.1 N 
acetic acid, emulsified with incomplete Freund's adjuvant and 
injected intradermally into the skin on the back of Wistar 
outbred rats. After a latent interval of about 2 weeks "'40% of 
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the rats developed an inflammatory polyarthritis. This arthritis 
was often severe and resulted in almost complete destruction of 
the joint with eventual bony ankylosis (Fig 1). Two other 
courses of disease have also been observed. Arthritis was some­
times transient. The limb became inflamed but over a period of 
3-7 days the inflammation subsided without residual effects. 
Occasionally arthritis was relapsing and underwent one or more 
exacerbations. Both of the latter courses were less common and 
were seen in only ",20% of affected rats. The histopathology of 
well developed but still early arthritis consisted of (1) synovitis 
with proliferation of synovial cells and eventual pannus for­
mation, (2) subsynovial infiltration with polymorphonuclear 
leukocytes and mononuclear cells, (3) exudation of cells into 
the synovial space, (4) development of marginal erosions, and 
(5) periostitis extending along the bone but apparently origi­
nating at the marginal region (Fig 2). 
Only native type II collagen was effective in inducing arthri­
tis. When other types of collagen were used for immunization 
no arthritis was detected. In fact, gently denaturing type II 
collagen by heating it to 45° for 15 min abrogated the arthritic 
response. Type II collagen from a variety of sources was an 
effective inducer of arthritis including human, bovine and ho­
mologous articular cartilage, chick sternal cartilage and bovine 
vitreous. The ability of homologous cartilage to induce arthritis 
was interesting and suggested that autoimmune reactions might 
be involved. The ability of type II collagen from vitreous to 
induce disease helped exclude the possibility that a copurified 
contaminant was responsible for the arthritis since the noncol­
lagenous matrix of vitreous is different from that of cartilage. 
Concomitant with arthritis an immune response to type II 
collagen could be detected in immunized animals with greater 
reactivity detected in arthritic as compared to nonarthritic rats 
[2,3]. Cellular immunity was measured using a lymphocyte 
proliferative assay. Lymph node cells were cultured in the 
presence of collagen for four days and pulsed with :lH-thymidine 
during the last 4 hr of culture. Cells from arthritic rats had a 
higher response than cells from nonarthritic rats. Humoral 
immunity was measured using a radioimmunoassay. Higher 
antibody levels to type II collagen were found in arthritic as 
compared to nonarthritic rats (Fig 3). These data suggested 
that an immune response to native type II collagen was inti­
mately involved with the occurrence of arthritis. 
Additional evidence of the importance of collagen immunity 
to the development of arthritis was provided by Trentham and 
colleagues who transferred disease from immunized donors to 
syngeneic unimmunized recipients with cells [4]. They obtained 
spleen and lymph nodes from donor rats 14-16 days after 
immunization with type II collagen and gave 5-50xlOH pooled 
cells intravenously to recipients. Cells from both arthritic and 
non-arthritic donors would transfer disease with an overall 
incidence of 28% in recipients, however, neither cellular nor 
humoral sensitivity to collagen was detected in recipients. Fur­
thermore, the cell responsible for transfer of arthritis was not 
identified. This study confIrmed the importance of immune 
cells in the development of arthritis but did not determine why 
they were important. 
There have been 2 studies of strain susceptibility to arthritis 
[5,6]. Both found that arthritis was probably under genetic 
control. One of the studies also measured skin test reactivity 
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FIG 1. Arthritic hindpaw from a Wistar rat immunized 2 weeks 
before this picture was taken with native type II collagen. The contra­
lateral hindpaw was uninvolved. Swelling and redness began at the 
ankle joint and spread over the entire dorsum of the foot. 
FIG 2. Histopathology of an arthritic rat ankle. This section was 
taken 3 days after the onset of severe arthritis. There is marked synovial 
proliferation and cellular inftltration. A marginal erosion can be noted 
and early destructive changes have occurred in the cartilage. 
and found a correlation between the skin test response and 
arthritis. The other study measured antibody levels and found 
a correlation between antibody levels and arthritis. Neither 
study measured both cellular and humoral immunity. 
While several groups of investigators agreed that the critical 
element in development of arthritis was an immune response 
to native type II collagen, the exact mechanism by which this 
occurred remained obscure. Recently we performed some ex­
periments which may clarify the immunopathologic events 
which result in arthritis. We immunized Wistar outbred rats 
with type II collagen and when arthritis was first detected, 
exsanguinated them and collected the sera. Sera from arthritic 
and non-arthritic rats were separately pooled and fractioned by 
precipitation with 50% ammonium sulfate. The precipitate was 
collected by centrifugation, redissolved in a minimal volume of 
water and dialyzed against phosphate buffered saline. After 
dialysis the serum concentrate was sterilized by millipore fIltra­
tion and administered intravenously to unimmunized Wistar 
rats. Those animals which received serum from arthritic rats 
subsequently developed arthritis. Those which received serum 
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from nonarthritic rats did not (Fig 4). Control serum concen­
trate prepared from normal rat serum also did not cause ar­
thritis in recipients. Passively transferred arthritis occurred in 
essentially all of the recipients which received adequate quan­
tities of transfer serum. It developed between 18 and 72 hr after 
transfer and was maximally severe within 24 hr of onset. It did 
not, however, achieve the severity of arthritis usually seen after 
immunization and was invariably transient. All of the arthritic 
recipients recovered within one week without either clinical or 
histopathologic evidence of sequelae. 
The histopathology of passively transferred arthritis was 
examined and we found that all of the major characteristics of 
arthritis in immunized animals were present in passively trans­
ferred arthritis. In particular there were synovitis with marginal 
erosions (Fig 5). The prominence of synovitis has always been 
of some concern to us. Type II collagen in the joint is found in 
the cartilage and is not known to be present in synovial tissue. 
Furthermore, the cartilage is relatively well preserved in early 
disease. 
With this concern in mind we addressed the question, what 
is the component of serum responsible for transfer of disease? 
The most likely explanations were (1) a circulating immune 
complex and (2) direct binding of an anticollagen antibody to 
autologous collagen. Other explanations were also possible in­
cluding the presence of some mediator that would directly 
activate cells to react with collagen but these explanations were 
considered less likely. A circulating immune complex etiology 
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FIG 3. Time course of the immune response to collagen in Wistar 
rats immunized with native type II collagen. Cellular proliferation 
(----) was measured by 3H-thymidine incorporation in lymph node cells 
cultured in the presence of native type II collagen. Antibody levels 
were measured by radioimmunoassay of an aliquot of serum using goat 
anti-rat IgG as a second antibody (-). Arthritic (. e), Nonarthritic 
(DO). 
PAS S IVE T RANSFER 
1. IMMUNIZE WISTAR OUTBRED RATS WITH NATIVE TYPE II COLLAGEN. 
2. EXSANGUINATE ARTHRITIC RATS 14-16 DAYS LATER. POOL SERA. 
EXSANGUINATE NON-ARTHRITIC RATS 21 DAYS LATER. POOL SERA. 
3. ADD E Q UAL VOLUME OF SATURATED SOLUTION OF AMMON IUM SULFATE 
TO EACH POOL. UlLLECT PRECIPITATE BY CENTRIFUGATION. 
4. REDISSOLVE PRECIPITATE IN A MINIMAL VOLUME OF WATER. 
5. DIALYZE AGAINST PHOSPHATE BUFFERED SALINE. ADJUST VOLUME 
TO 1/2 THAT OF SERUM POOL. STERILIZE BY MILLIPORE 
FILTRATION. 
6. ADMINISTER SERUM CONCENTRATE TO UNIMMUNIZED RECIPIENTS 
INTRAVENOUSLY. 
2,5ML ARTHRITIC SERUM CONCENTRATE�ARTHRITIS 
2,SML NON-ARTHR I 11 C SE RUM CONCENTRATE - NO ARTHR I TIS 
FIG 4. Outline of the procedure used to obtain serum concentrate 
for passive transfer of arthritis. 
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FIG 5. Histopathology of an arthritic joint from a rat which received 
2.5 ml of serum concentrate 48 hr before the section was obtained. 
Definite synovitis is noted but there is ralative sparing of the cartilage. 
was the most attractive since it would explain the prominence 
of synovitis and the observation that high antibody levels are 
occasionally found in the absence of arthritis. Several ap­
proaches to identifying immune complexes in serum were un­
dertaken (1) Serum from acutely arthritic rats was assayed for 
the presence of immune complexes by radioactive Clq binding. 
In this assay serum from both normal and acutely arthritic rats 
showed less than 10% binding. If collagen was added to the 
serum of arthritic rats prior to assay or if normal serum was 
heated to 60° for 5 min then >25% binding was detected. (2) 
Collagenase was added to serum concentrate in an attempt to 
digest the collagenous portion of the complex and destroy the 
ability of the concentrate to transfer arthritis. However, the 
concentrate retained fully its ability to transfer arthritis after 
collagenase digestion. This could not have been due to protec­
tion of collagen by the antibody since collagen in complexes 
formed in vitro was susceptible to collagenase. (3) Rats were 
immunized with radiolabeled collagen and arthritic joints sub­
jected to scintillation spectrometry. No radioactivity was de­
tected in the serum or joints of arthritic rats. By all of the 
methods used, no evidence of immune complexes could be 
detected (Fig 6). 
Therefore, further purification of the active substance was 
attempted. An affinity column was made using native type II 
collagen bound to Sepharose. When the serum concentrate was 
placed on the column at neutral pH and the column was washed 
with phosphate buffered saline (PBS), the activity was retained 
by the column. The activity could be recovered by elution with 
glycine HCI, pH 2.8. When the acid eluate was subjected to gel 
flltration chromatography on Biogel A5m, the arthritogenic 
activity eluted coincident with the IgG marker. In all cases, 
activity was detected by dialyzing the recovered material 
against PBS, concentrating it to a volume of 2ml by pressure 
dialysis, sterilizing it by microporous flltration and administer­
ing it intravenously to unimmunized rats (Fig 7). 
The purified active transfer material consisted primarily of 
IgG antitype II collagen antibodies. The identity of the transfer 
material was established by immunoelectrophoresis and by 
Ouchterlony double diffusion against anti-rat IgG, anti-rat IgM 
and anti-rat whole serum. By Ouchterlony double diffusion a 
line of identity formed with rat IgG when tested against anti­
IgG and anti-whole serum. Only one line was seen against anti­
whole serum and no line was seen against anti-IgM (Fig 8). 
When assayed by ELISA the reactivity of the purified transfer 
antibody was specific for the native bovine type II collagen 
used for immunization and did not react with other types of 
collagen or with denatured type II collagen. They did, however, 
cross-react with rat type II collagen. Since immune complexes 
could not be detected, we postulate that arthritis was caused 
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by anti-native type II collagen antibodies which localized to the 
joint by binding to autologous type II collagen. Proof of that 
hypothesis will depend on identification of specific antibodies 
in the joint. 
EVIDENCE AGAINST CIRCULATING IMMUNE COMPLEX 
1. SERUM FROM ACUTELY ARTHRITIC RATS DID NOT HAVE IMMUNE 
COMPLEXES BY RADIOACTIVE C1q BINDING. ADDITION OF 
COLLAGEN IN VITRO - .. DEF I N ITE Clq B I NO I NG. 
2. COLLAGENASE DIGESTION OF SERuM CONCENTRATE DID NOT 
AFFECT ABILITY TO TRANSFER DISEASE BUT WOULD REMOVE 
COLLAGEN FROM COMPLEXES FORMED iN VIIBO. 
3. IMMUNIZATION WITH RADIOLABELED COLLAGEN INDUCED 
ARTHRITIS BUT NO LABEL WAS DETECTED IN JOINTS OR 
SERUM. 
FIG 6. Summary of the evidence against circulating immune com­
plex as a cause of the arthritis. 
Arthritic Rot Serum 
Sepharose Type 
N
�
t
��I agen 
0 + -V 
c 
6 
6 
PBS eluate -No Arthritis 
2. Acid eluate -Arthritis 
FIG 7. Diagram of the assembly of the collagen-Sepharose affinity 
column used to absorb the active transfer factor from rat serum. 
FIG 8. Ouchterlony gel diffusion showing the reaction between rab­
bit antirat IgG (A) and rabbit antirat IgM (E) against the purified 
transfer fraction (T), rat whole serum (8) and purified rat IgG (0) or 
IgM (M). Purified transfer fraction was obtained by 50% ammonium 
sulfate precipitation followed by type II collagen-sepharose affinity 
chromatography followed by gel fIltration on Biogel A5m. Rat IgG and 
IgM were obtained commercially. 
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These studies showed that antibodies to native type Il col­
lagen were capable of inducing an inflammatory polyarthritis 
which histopathologically resembled the arthritis that devel­
oped after immunization of rats with native type II collagen. 
They do not address the question of the role of cellular immu­
nity in collagen-induced arthritis. It is not known whether 
cellular reactivity can also initiate arthritis or if it can aggravate 
or potentiate arthritis initiated by antibodies. The passively 
transferred arthritis we observed was transient but it resulted 
after a single injection of serum. Whether cellular reactions or 
repeated injection of antibody would produce more severe 
disease with chronic changes is not known. 
We have recently shown that immunization of rats with 
native type II collagen has consequences other than the devel­
opment of arthritis. Some of the immunized animals also de­
velop inflammatory ear lesions [7]. These lesions occur in 159<' 
of Wistar outbred rats immunized with native bovine type II 
collagen. They begin as small red nodules which are often 
multifocal . The nodules enlarge and frequently coalesce so that 
the entire ear may eventually become red and thickened (Fig 
9). When examined histologically this lesion appears to be the 
result of an underlying chondritis (Fig 10). Cells accumulate in 
the perichondrium and invade the cartilage plate. Over a period 
of several days the cartilage plate is completely destroyed by 
invading inflammatory cells . Finally small areas of regenerating 
cartilage are seen in the center of the inflammatory mass but 
these lack the organization of the original ear plate.' 
Chondritis appears later than the arthritis and is apparently 
unrelated to arthritis. The main day of onset of chondritis is 
49.8 ± 5.2 days, whereas, arthritis begins at 13.4 ± 0.4 days. 
About one third the rats with chondritis are not arthritic. In 
addition , we have rarely seen chondritis in Wistar/Lewis inbred 
rats. Immunofluorescent staining of the lesion shows the pres­
ence of IgG and C3. Because anti-type II collagen antibodies 
are also found in human relapsing poly chondritis [8], we believe 
this lesion may represent an animal model of relapsing poly­
chondritis. 
If both arthritis and chondritis are caused by anticollagen 
antibodies , why do they not appear simultaneously or at least 
in the same rats'? At the present time we cannot answer that 
question but several possibilities exist. (l) Local factors may be 
FIG 9. Shown is the appearance of an ear nodule in a Wistar rat 
immunized with native type II collagen 5 weeks before the picture was 
taken. 
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FIG 10. Histopathology of a well-developed ear nodule showing the 
marked destruction of the cartilage plate with regenerating nodules of 
cartilage. 
important. Certainly the thick perichondrium of ear is different 
from the thin synovial lining of the joint and the perichondrium 
is adherent to the cartilage, whereas the joint surface is not 
covered with a membrane. (2) The antibodies involved in 
chondritis may have specificity for different epitopes. Late in 
the immune response antibodies of specificity for minor epi­
topes on native type II collagen may accumulate. (3) Finally, 
while we have eliminated circulating immune complexes as 
cause of arthritis, we have not investigated their role in chon­
dritis. Investigations of relapsing polychondritis in humans have 
shown some association between immune complexes and chon­
dritis [9]. 
It has recently been reported that immunization with type II 
collagen will also induce arthritis in some strains of mice [10]. 
Bovine type II collagen was given in an emulsion with either 
complete or incomplete Freund's adjuvant by multiple intra­
dermal injections into the skin on the back. It was reported that 
there was marked strain variation in susceptibility to arthritis . 
We have successfully induced arthritis in the DBA/l mouse 
from Jackson Laboratories (Fig 11). However, we have modified 
the previously reported immunization procedure considerably. 
We found that immunization with bovine, chick and rat type II 
collagen would all induce arthritis in DBA/1 mice but in our 
hands chick and rat collagen were much more effective. Also 
administration of a single injection of native type II collagen 
emulsified in complete Freund 's adjuvant intradermally into 
the tail gave a higher incidence of arthritis than multiple 
injections on the back. We now give 25 Ilg of native chick type 
II collagen in 0.05 ml of emulsion with complete Freund's 
adjuvant. Under these conditions an incidence of arthritis of 
greater than 90% is regularly achieved in DBA/l mice. 
There are several differences between collagen-induced ar­
thritis in mice and rats. The most striking difference is time of 
onset. Mice rarely develop arthritis before 3 weeks after im­
munization. Usually the onset is between 4-5 weeks while the 
mean day of onset for collagen-induced arthritis in rats in our 
laboratory is 13.4 ± 0.4 days. Mice are also more likely to have 
early forepaw involvement or at least forepaw involvement is 
simultaneous with disease onset. In rats forepaw involvement 
is at 33.8 ± 3.6 days or nearly a weeks later than hindpaw 
disease. Ear nodules are also very rare in mice. Despite these 
differences the histopathology of the arthritis is very similar in 
both species. 
When genetic control of the susceptibility to arthritis in mice 
was studied, it was found that arthritis was linked to the Ir 
region of the H-2 major histocompatability locus (Table II) 
[11]. By studying recombinant strains, it was found that arthri­
tis was associated with the Iq haplotype and was dominant in 
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FIG 11. The appearance of arthritis in a DBA/I mouse immunized 
with native type II collagen. Arthritis developed ao days after immu­
nization and this photograph was taken 3 days later. 
TABLE LAbility oj" variuus collagens to induce arthritis 
---- -- ._--- ---_. 
Collagen (source)" Arthritis Incidence 
-----_. 
Type I (human skin) 
Type II (bovine articular cart.) 
(bovine vitreous) 
(chick sternal carL) 
(tat articular carlo) 
Type III (human skin) 
Type IV (human placenta) 
Type V (human placenta) 
Type "M" (bovine articular cart.) 
OlIO 
7/10 
8/10 
4/10 
2/10 
OliO 
OlIO 
OlIO 
OlIO 
" Collagen was dissolved at a concentration of 2 mglml in 0.1 N acetic 
acid by stirring overnight. An emulsion was made using a Virtis ho­
mogenizer and equal volumes of collagen solution and incomplete 
Freund's adjuvant. All of the procedures were performed at 4°C or on 
an ice bath to avoid denaturation of the collagen. Each rat received 0.1 
ml of emulsion by intradermal injection into the right hind footpad. All 
rats were observed fOl" 4 weeks for the development of arthritis. 
TABLE II. 
Strain 
DBA/1 
C57Bl 
B lO.D2 
BlO.RIII 
CBA/N 
DBA/2 
BlO.BR 
BlO.wB 
BlO.PL 
BlO.5M 
Susceptibility oj" mice with various H-2 haplutypes to 
arthritis" 
------_.--_ .. --
H-2 Haplotype Arthritis Antibody level 
q +++ High 
b + High 
d 0 High 
0 Intermediate 
s 0 Intermediate 
d 0 Low 
k 0 Low 
0 Low 
u 0 Low 
v 0 Low 
" Data was compiled from references 10, 11, and personal observa­
tions. 
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F I animals . All strains which developed arthritis had high 
antibody levels to type II collagen. There were, however , strains 
identified which had a high antibody response but did not 
develop arthritis . 
When the DBAII mouse was extensively studied to deter­
mine the nature of the immune response to collagen , we made 
several interesting observations. Cellular reactivity measured 
by lymphocyte proliferation developed rapidly and peak reac­
tivity was detected at 2 weeks after immunization (Fig 12). IgM 
antibody levels measured by ELISA also peaked at 2 weeks. 
Arthritis developed much later, between 4 and 5 weeks after 
immunization, coincident with the peak of IgG reactivity as 
measured by ELISA. When the specificity of the immune 
response to collagen was analyzed , it was found that lymphocyte 
proliferation could be stimulated equally well with native t.vpe 
II collagen, denatured type II collagen or with type I collagen. 
In addition, culture of cells with denatured collagen followed 
by killing of the proliferating cells with BUDR and light and 
restimulating the cells with native collagen did not yield a 
detectable response. Native collagen would not stimulate cul­
tures from which cells responding to denatured collagen had 
been eliminated. There seemed to be no specificity of the 
proliferative response for conformation-dependent determi­
nants or even for the type of collagen. Antibody specificity was 
also analyzed in these mice . It was found that the antibody 
response was highly specific for conformational determinants 
on native type II collagen. Denatured type II collagen and type 
I collagen would not inhibit the binding of antisera from ar­
thritic mice in the ELISA assay. 
Based on our studies of collagen-induced arthritis in rats and 
mice, we have formulated a general hypothesis stating our 
current view of the etiology of arthritis in these species . In the 
first place, it seems likely that despite a number of differences 
in the onset and clinical course of arthritis, similar mechanisms 
are involved in both species . Since the arthritis depends on 
immunization with native type II collagen , an immune response 
specific for conformational determinants on native type II col­
lagen must be involved. Antibodies with the required specificity 
have been demonstrated in both rats and mice. These anti­
bodies have been shown to be capable of inducing arthritis in 
rats and have been strongly associated with arthritis in mice. 
We would suggest that binding of these antibodies to autologous 
type II collagen initiates arthritis. Genetic control of the anti­
body response determines susceptibility to arthritis. Although 
cell-mediated immunity also develops in immunized animals, it 
is directed at covalent structural determinants on the type II 
collagen molecule and probably does not initiate joint damage, 
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FIG 12. Time course of the immune response to type II collagen in 
DBA/l mice. Cellular proliferation was measured by culturing spleen 
cells in the presence of collagen and measuring "H-thymidine incorpo­
ration (--0--). Antibody levels were measured by ELISA assay using 
native type II collagen-coated plates and peroxidase conjugated antirat 
IgM (-o-) or antirat IgG (-e-). 
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TABLE III. Frequency of antibodies to collagen in RA (% positive)" 
Serum 
Synovial fluid 
38 
35 
II 
22 
21 
Native 
III 
21 
47 
IV 
21 
21 
v 
8 
11 
dI 
88 
94 
dII 
38 
74 
Denatured 
dIII 
50 
69 
dIV 
42 
95 
dV 
74 
58 ----------------------------------------------------------------------------------------------------
" Antibody levels were measured by radioimmunoassay of '""I-labeled collagen and goat anti-human IgG 2nd antibody. Any serum precipitating 
labeled collagen in an amount greater than 2 standard deviations above the mean of 10 normal control sera was considered positive (method of 
reference 21). 
although it may contribute to inflammation and to joint de­
struction after the initial injury occurs. 
While our studies have concentrated on collagen-induced 
disease, there are at least two other animal models of disease in 
which collagen autoimmunity has been implicated. The first of 
these is adjuvant arthritis in rats. This disease was described 
by Pearson in 1956 [12). Both clinically and histologically, the 
arthritis resembles collagen-induced arthritis in many respects. 
Because of these similarities we undertook a study of type II 
collagen for adjuvant activity several years ago [13). We were 
unable to detect adjuvant activity in our type II collagen 
preparation. Looking at the other side of the coin, Trentham 
and colleagues have described both cellular and humoral im­
munity to type II collagen in adjuvant arthritis [14). We have 
attempted to confIrm those findings but detected only very low 
levels of lymphocyte proliferation measure by :lH-thymidine 
incorporation in response to collagen or of antibodies as meas­
ured by ELISA. While low levels of collagen autoimmunity may 
be present in adjuvant arthritis, their role in the pathogenesis 
of disease has not been established. 
Finally, a spontaneous systemic sclerosis-like disease has 
been described in a certain inbred strain of chickens [15). These 
chickens have fIbrosis of the skin and esophagus and some 
involvement of other internal organs, many have polyarthritis. 
Several autoantibodies have been detected in their sera includ­
ing rheumatoid factor, antinuclear antibodies and anti-type II 
collagen antibodies. The significance of the anticollagen anti­
bodies is not known. There have been no studies of antibodies 
to other types of collagen or of cellular reactions to collagen in 
this animal model. The appearance of anticollagen antibodies 
spontaneously certainly is of interest. 
COLLAGEN AUTOIMMUNITY IN RHEUMATOID 
ARTHRITIS ( R A) 
Antibodies to collagen in RA were fIrst described by Steffen 
and Timpl in 1963 (16). Several years later Michaeli and Fu­
denberg confirmed the finding of anti collagen reactivity in RA 
but suggested that all of the activity could be accounted for by 
reaction with determinants on the denatured molecule and 
suggested that the reactivity might be secondary to tissue 
destruction and not of etiologic importance. Both of these early 
studies were performed using type I collagen, however. In 1976, 
Andriopoulous and coworkers found that there were antibodies 
in RA to types II and III collagen and to the denatured CI chain 
components of these collagens. Again greater reactivity was 
found in response to the denatured components [17). It was 
found that 77%, 71%, and 62% of RA patients had antibody 
titers greater than 1:S when tested against native types I, II and 
III collagen, respectively by hemagglutination. There were SS% 
and SI % of patients responding to denatured types I and II 
collagens, respectively. 
Other investigators have reported that anticollagen anti­
bodies were also present in 12 of 29 RA synovial fluids [IS]. 
Treatment of synovial fluid with collagenase resulted in an 
increased titer in 9 and the appearance of detectable antibodies 
in 6 additional fluids which were negative prior to collagenase 
digestion.  Using a radioimmunoassay Menzel et al found anti­
bodies to type I collagen in 20 of 29 RA synovial fluids [19]. 
We have extended observations of collagen reactivity in sera 
and synovial fluid and have found reactivity with types IV and 
V collagen (Table III) [20). Like previous investigators, we 
found greater reactivity with the denatured components. The 
method we used was a radioimmunoassay with 12°1 labeled 
collagen that has proven to be a sensitive means of detecting 
antibody reactivity in collagen-induced arthritis in rats [21]. 
Most previous studies have used hemagglutination although 
some have used a radioimmunoassay with 14C-labeled collagen. 
Despite the sensitivity of our assay when used with rodent sera, 
we detected antibodies to collagen in fewer RA patients than 
was reported by Andriopoulos et al. This may have been due to 
differences in the patient population or technical differences. 
There is also evidence that patients with RA have cellular 
sensitivity to collagen. Trentham et al used a leukocyte inhibi­
tory assay to detect lymphocyte reactivity in cells cultured in 
the presence of types I, II, and III collagen [22]. They found 
that only native types II and III collagen would stimulate cells 
and suggested that type specific cellular reactions to collagen 
might account for the localization of lesions in RA. We have 
also tested RA patients for cellular reactivity to collagen [23). 
Peripheral blood mononuclear cells were isolated and cultured 
in the presence of native and denatured types I, II, and III 
collagen. The supernatant fluids from these cultures were har­
vested and assayed for lymphocyte-derived chemotactic factor 
for monocytes (LDCF). It was found that all 3 types of collagen 
tested would stimulate the production of LCDF by RA cells 
but not cells from normal individuals (Table IV). We also found 
greater reactivity to denatured collagen than to native collagen. 
Our data suggested that cellular reactivity was greatest in 
response to covalent structural determinants and was not type­
specifIc. Solinger et al have also tested RA patients for collagen 
reactivity by measuring leukocyte inhibition factor production 
by peripheral blood cells cultured with denatured collagen 
[24]. They found reactivity in 90% of RA patients and in 30% of 
controls. There was a highly significant association with HLA­
DRw4 in both groups. Thus, collagen reactivity in man may be 
under genetic control and may be associated with a haplotype 
which in turn is strongly associated with RA [25]. 
Our present understanding of collagen autoimmunity in RA 
may be summarized as follows: (1) patients with RA have both 
cellular and humoral immunity to collagen; (2) the cellular 
reactivity is probably directed at covalent structural determi­
nants (denatured collagen) and is not specific for any one type 
of collagen; (3) cellular reactivity may be under genetic control 
specifically by a gene associated with HLA-D Rw4; (4) humoral 
reactivity in RA has usually been found to be greater in response 
to covalent structural determinants. The last point is of impor­
tance when considered in the light of our previously stated 
hypothesis regarding collagen-induced arthritis in rodents. We 
TABLE IV. Cellular reactivity to collagen in RA ('lc positive)" 
Native Denatured ----------- ------------
II III dI dII dIll ------------------------------------- ----------
45 50 50 80 90 90 
"Cellular immunity in RA was measured by culturing peripheral 
blood mononuclear cells with each collagen and assaying the culture 
supernatant fluids for lymphocyte-derived chemotactic factor for mono­
cytes. Cells were also obtained from 10 normal subjects as controls and 
values above 2 standard deviations from the mean were considered 
positive (method of reference 23), 
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feel the most important initiator of collagen-induced arthritis 
may be an antibody specific for conformational determinants 
on native type II collagen, a reaction which is not the major 
one detected in RA. One additional bit of information needs to 
be mentioned, however. Some investigators have identified 
antibodies specific for conformational-determinants on native 
type II collagen in a few patients selected for high anticollagen 
antibody activity [26,27]. Whether the specificity is the same as 
that seen in collagen-induced arthritis in rodents is not known. 
At present we can state only that there is suggestive evidence 
of an association between RA and autoimmunity to collagen. 
There are many similarities between collagen-induced arthritis 
in rodents and human RA but there remain significant differ­
ences. 
COLLAGEN AUTOIMMUNITY IN OTHER DISEASES 
While numerous reports of collagen autoimmunity in RA 
have been published, much less is known about collagen auto­
immunity in other diseases. We have investigated systemic 
sclerosis and found evidence of cellular reactivity to both native 
and denatured type I collagen [28] . The reaction has not been 
well characterized but study of a few patients found it not to be 
different from what we found in RA. We have not investigated 
humoral reactivity in systemic sclerosis. It has previously been 
reported that antibodies to denatured type I collagen are de­
tectable [29] .  Kravis et al have reported that patients with 
idiopathic pulmonary fibrosis also have cellular reactivity to 
collagen as measured by production of migration inhibition 
factor by cells cultured in the presence of type I collagen [30] . 
There have also been at least 2 reports of antibodies to dena­
tured type I collagen in chronic liver disease [31 ,32] . Based on 
these observation it would be possible to speculate about com­
mon pathogenetic mechanisms causing a variety of fibrosing 
conditions. However, the data would j ust as easily support the 
idea that many chronic fibrosil�g diseases lead tc exposure of 
collagen and that immune reactivity to collagen frequently 
develops secondarily. 
Relapsing polychondritis is an infrequently diagnosed condi­
tion associated with anti-type II collagen antibodies but it was 
already discussed in connection with collagen-induced disease 
of rats. 
CONCLUDING REMARKS 
Collagen autoimmunity appears to be a relatively common 
event particularly in rheumatic diseases. Perhaps more diligent 
investigation will reveal its presence in many nonrheumatic 
diseases as well. Because of the lack of disease specificity, it is 
at present impossible to ascribe a definite pathogenic role to 
collagen autoimmunity in any human disease. The approach 
we have taken is to attempt thorough understanding of the 
pathophysiology of collagen immunity in an animal model and 
to relate this to more specific findings in human disease. This 
approach has its limitations but in the case of autoimmune 
arthritis in rodents it appears defmite progress is being made. 
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